Rigel Pharmaceuticals (RIGL)Gross Margin: ~89% - 92%
Sales Growth (Q/Q): ~40% - 60%
P/E (Current),~6.1 - 6.3,"Extremely low. The market is still cautious, which offers potential for a ""value"" investment."
Forward P/E,~10.8,"Slightly up from current, reflecting expected R&D investments in 2026."
Free Cash Flow,~$77M (for
Rigel Pharmaceuticals, Inc.
No trades
No trades
Compare with Rigel Pharmaceuticals, Inc.
17.67 USD
367.02 M USD
294.28 M USD
18.06 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
CEO
Raul R. Rodriguez
Website
Headquarters
South San Francisco
Founded
1996
IPO date
Nov 29, 2000
ISIN
US7665597024
CUSIP
766559702
FIGI
BBG000BPWTW7
Identifiers
ISIN US7665597024
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
1/21/25 - RIGL: new BUY mechanical trading signal.1/21/25 - RIGL: new BUY signal chosen by a rules based, mechanical trading system.
RIGL - BUY
Stop Loss @ 16.25
Entry BUY @ 21.81
Target Profit @ 27.80
Analysis:
Higher timeframe: Prices have stayed above the lower channel line of the ATR (Average True Range) Keltner Channel and reversed.
Highe
Watchlist 2023-03-07 $OPK $RIGL $WE SPY - flat this morning as we await the second testimonial day for FED chair Powell. There has been lots of opportunity in small caps the past week so shifting focus there, also to avoid the chop that we see in large cap on Fed days.
OPK - Opko health sign deal for experimental Epstein-Barr virus
RIGL - trending upwardsLooking to take an entry at 1.05 if volume and technicals look promising for Monday. A break below $1 would turn this into a bearish play for me.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders (or potential shareholders) will be happy to see that the President, Raul Rodriguez, recently boug
Rigel Pharmaceuticals doing a thing. RIGLNot quite going to Rigel, but showing more and more promise of higher highs in the not so distant future. Looking quite optimal fractally, actually.
Fibonacci goals are in green, reversal or invalidation is in red. This post is not financial advice, make your own financial advice or pay a certified
See all ideas
Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral
An aggregate view of professional's ratings.
Neutral
Neutral
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
Today, RIGL trades at 48.86 USD.
For broader market analysis, dive into the technicals on the Rigel Pharmaceuticals, Inc. stock price chart and read the latest RIGL news:
– Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
– Rigel Pharmaceuticals Price Target Maintained With a $85.00/Share by HC Wainwright & Co.
– HC Wainwright & Co. reiterates Buy rating on Rigel Pharmaceuticals, $85 price target
For broader market analysis, dive into the technicals on the Rigel Pharmaceuticals, Inc. stock price chart and read the latest RIGL news:
– Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
– Rigel Pharmaceuticals Price Target Maintained With a $85.00/Share by HC Wainwright & Co.
– HC Wainwright & Co. reiterates Buy rating on Rigel Pharmaceuticals, $85 price target
Markets don't sleep, here's what's going on with RIGL at the moment:
– Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
– Rigel Pharmaceuticals Price Target Maintained With a $85.00/Share by HC Wainwright & Co.
– HC Wainwright & Co. reiterates Buy rating on Rigel Pharmaceuticals, $85 price target
See more updates in real-time with our News Flow.
– Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
– Rigel Pharmaceuticals Price Target Maintained With a $85.00/Share by HC Wainwright & Co.
– HC Wainwright & Co. reiterates Buy rating on Rigel Pharmaceuticals, $85 price target
See more updates in real-time with our News Flow.
Rigel Pharmaceuticals, Inc. is scheduled to release its next earnings report on Nov 5, 2026.
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
RIGL stock is 9.40% volatile and has beta coefficient of 1.27.
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like RIGL are typically less volatile than smaller companies
Track every detail on Rigel Pharmaceuticals, Inc. stock chart and check out the list of the most volatile stocks — is Rigel Pharmaceuticals, Inc. there?
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like RIGL are typically less volatile than smaller companies
Track every detail on Rigel Pharmaceuticals, Inc. stock chart and check out the list of the most volatile stocks — is Rigel Pharmaceuticals, Inc. there?
To understand the RIGL stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — −0.85%
– 1 week — +0.02%
– 1 month — +5.12%
RIGL all-time low was 6.40 USD (Jun 13, 2022), and its highest price is 1,147.50 USD (Jan 3, 2001). Find more dynamics in the Stock Heatmap and on the Rigel Pharmaceuticals, Inc. stock chart.
– 1 day — −0.85%
– 1 week — +0.02%
– 1 month — +5.12%
RIGL all-time low was 6.40 USD (Jun 13, 2022), and its highest price is 1,147.50 USD (Jan 3, 2001). Find more dynamics in the Stock Heatmap and on the Rigel Pharmaceuticals, Inc. stock chart.
Rigel Pharmaceuticals, Inc. market capitalization is 912.70 M, representing the total value of all its outstanding shares (price × shares outstanding).
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Rigel Pharmaceuticals, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Rigel Pharmaceuticals, Inc. stacks up against other companies
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Rigel Pharmaceuticals, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Rigel Pharmaceuticals, Inc. stacks up against other companies
The safest way to buy Rigel Pharmaceuticals, Inc. stocks is through a reliable broker. Create an account, fund it, and place a buy order.
You can trade RIGL directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
You can trade RIGL directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
As of Nov 4, 2026, the company has 174 employees.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Investing in Rigel Pharmaceuticals, Inc. depends on your goals, risk tolerance, and market conditions. It’s essential to analyze the stock before making a decision.
First, study Rigel Pharmaceuticals, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our RIGL technicals – signals based on essential indicators calculations:
– Today — buy
– 1-week — buy
– 1-month — buy
Combine fundamental and technical analysis for better results.
First, study Rigel Pharmaceuticals, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our RIGL technicals – signals based on essential indicators calculations:
– Today — buy
– 1-week — buy
– 1-month — buy
Combine fundamental and technical analysis for better results.
Rigel Pharmaceuticals, Inc. stock ticker depends on the exchange where it’s listed. On the NASDAQ, its primary exchange, Rigel Pharmaceuticals, Inc. stocks trade under the symbol RIGL.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
RIGL earnings for the last quarter are 0.88 USD per share, whereas the estimation was 0.09 USD, resulting in a 903.88% surprise. The estimated earnings for the next quarter are 0.92 USD per share.
How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one
Follow other essential metrics in Rigel Pharmaceuticals, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one
Follow other essential metrics in Rigel Pharmaceuticals, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
Rigel Pharmaceuticals, Inc. revenue for the last quarter amounts to 78.70 M USD despite the estimated figure of 55.27 M USD. In the next quarter revenue is expected to reach 80.10 M USD.
How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance
Follow other essential metrics in Rigel Pharmaceuticals, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses
How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance
Follow other essential metrics in Rigel Pharmaceuticals, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses
Yes, you can track Rigel Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
RIGL net income for the last quarter is 17.29 M USD, while the quarter before that showed 8.65 M USD of net income which accounts for 99.79% change.
How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result
Follow other essential metrics in Rigel Pharmaceuticals, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result
Follow other essential metrics in Rigel Pharmaceuticals, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
No, Rigel Pharmaceuticals, Inc. does not currently pay dividends to its shareholders.
Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.
What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.
What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
RIGL reached its all-time high of 1,147.50 USD on Jan 3, 2001. Its all-time low was 6.40 USD and was reached on Jun 13, 2022.
Explore the Rigel Pharmaceuticals, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Explore the Rigel Pharmaceuticals, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Rigel Pharmaceuticals, Inc. EBITDA is 89.70 M USD, with an EBITDA margin of 43.46%.
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Rigel Pharmaceuticals, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Rigel Pharmaceuticals, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
Analyst forecasts suggest a price range between 43.00 USD and 85.00 USD for RIGL, based on current estimates.
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance









